Indiana Lions Eye Bank distributed ocular tissue from donors with sepsis after failing to screen them as ineligible.
What happened
FDA inspected the Carmel, IN facility from January 22 to February 1, 2024, and documented deviations on a Form FDA-483, the list of inspection observations. FDA found that from January 2021 to January 2024 the company determined five ocular HCT/P donors eligible even though their records showed diagnoses or clinical evidence of sepsis, including systemic responses to infection, before death. Ocular HCT/Ps from those donors were distributed.
What FDA found
FDA found that the company failed to determine as ineligible five donors who had documented sepsis or clinical evidence and systemic responses to infection during the hospital stay before death.
21 CFR 1271.75(d); 21 CFR 1271.75(a)(1)The company’s donor eligibility procedure and sepsis flowchart did not include all clinical evidence and systemic responses to infection needed to evaluate sepsis risk.
21 CFR 1271.47(a)The sepsis flowchart used only two systemic responses to infection and omitted heart rate, respiratory rate or PaCO2, and severe signs such as hypoxemia, elevated lactate, oliguria, altered mentation, and hypotension.
21 CFR 1271.47(a)Because HCT/Ps were distributed, the letter states deviation reports must be submitted to FDA under the HCT/P deviation reporting rule.
21 CFR 1271.350(b)
What FDA wants
FDA asks the company to promptly correct the violations and respond in writing within 15 working days with specific corrective actions, how it will prevent recurrence, and supporting documentation. If all corrections cannot be completed in that time, FDA asks for the reason and a timeframe.
Who should pay attention
- eye banks and tissue banks
- transplant centers and eye surgeons using donor tissue
- quality teams that screen HCT/P donors
This is a summary. Read the original letter on fda.gov.